As described above, immunization with purified tumor-derived HSPs or HSPs complexed with an antigen peptide/protein in vitro elicits tumor- or antigen-specific CD8+ T cell responses (4–6, 17, 35, 36). This evidence concerns the gene CD8A and neoplasm.